EP. 1: Case 1: Newly Diagnosed CLL, IGHV-Unmutated
Watch
EP. 2: Case 1: Initiating Treatment for CLL
EP. 3: Case 1: Assessing Risk in CLL
EP. 4: Case 1: The Use of Ibrutinib in CLL
EP. 5: Case 1: Ibrutinib +/- CD20 Antibodies in CLL
EP. 6: Case 1: Ibrutinib in CLL
EP. 7: Case 2: Newly Diagnosed CLL; Del(17p)
EP. 8: Case 2: Frontline Treatments for CLL With Del(17p)
EP. 9: Case 2: MRD Testing in CLL
EP. 10: Case 2: Choosing Treatment for CLL With Del(17p)
EP. 11: Case 2: Sequencing Therapies in CLL
EP. 12: Case 3: Elderly Patient With Treatment-Naive CLL
EP. 13: Case 3: Managing Ibrutinib-Associated Toxicities in CLL
EP. 14: Case 3: Risk Assessment And Elderly Patients with CLL
EP. 15: Case 3: Intolerance to BTK Inhibitors in CLL
EP. 16: Case 4: A Patient With Relapsed/Refractory CLL
EP. 17: Case 4: Resistance to Ibrutinib in CLL
EP. 18: Case 4: Treatment of Relapsed CLL
EP. 19: Additional Insights: Treatment Regimens in CLL
EP. 20: Additional Insights: Management of Ibrutinib in CLL
